TY - JOUR
T1 - Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study
AU - Castro-Espin, C.
AU - Cairat, M.
AU - -S., Navionis A.
AU - Dahm, C. C.
AU - Antoniussen, C. S.
AU - Tjonneland, A.
AU - Mellemkjaer, L.
AU - Mancini, F. R.
AU - Hajji-Louati, M.
AU - Severi, G.
AU - Le, Cornet C.
AU - Kaaks, R.
AU - Schulze, M. B.
AU - Masala, G.
AU - Agnoli, C.
AU - SACERDOTE, Carlotta
AU - Crous-Bou, M.
AU - -J., Sanchez M.
AU - Amiano, P.
AU - -D., Chirlaque M.
AU - Guevara, M.
AU - Smith-Byrne, K.
AU - Heath, A. K.
AU - Christakoudi, S.
AU - Gunter, M. J.
AU - Rinaldi, S.
AU - Agudo, A.
AU - Dossus, L.
PY - 2024
Y1 - 2024
N2 - BackgroundInflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive. MethodsWe studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors. ResultsOver a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNF alpha were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-alpha was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58). ConclusionsHigher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNF alpha and inflammatory scores seem to predict all-cause mortality.
AB - BackgroundInflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive. MethodsWe studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors. ResultsOver a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNF alpha were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-alpha was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58). ConclusionsHigher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNF alpha and inflammatory scores seem to predict all-cause mortality.
UR - https://iris.uniupo.it/handle/11579/197186
U2 - 10.1038/s41416-024-02858-6
DO - 10.1038/s41416-024-02858-6
M3 - Article
SN - 1532-1827
VL - 131
SP - 1496
EP - 1505
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 9
ER -